Hims & Hers Health, Inc. Stock 12‑Month Price Target Cut to $31.72, Implies 38% Upside

What happened

Analysts’ average 12-month price target for Hims & Hers Health fell from $32.15 to $31.72, based on estimates from 14 analysts. The new target implies approximately 38% upside from the Nov. 9 closing price. The overall rating remained Hold among 19 analysts.

Confirmed

Global impact / market context

The lower average target signals that analysts have modestly reduced their expected value for the stock, even while the new target remains above the cited closing price. That gap can shape investor expectations, but it is not a forecast guarantee or a company performance result.

Analyst inference

The analyst picture is mixed but leans cautious: five of 19 analysts rate the shares Buy, 14 rate them Hold, and none rate them Sell. Forecasts from the 14 target contributors range from $24 to $42 per share.

Confirmed

What to watch

1. Watch for later analyst target changes and whether the average moves further from $31.72; the supplied article gives no company operating results or reasons for the reduction. Analyst inference
2. Compare future ratings with the current split of five Buys, 14 Holds, and zero Sells to see whether analyst views become more positive or cautious. Analyst inference
3. Treat the approximately 38% implied upside as a calculation from the Nov. 9 closing price, not as a promised return or investment recommendation. Confirmed

Evidence

• Original source link unavailable